Current
Neuro-Oncology

Volume 19 Number 8
31 August 2017

Home > Publications > Current Neuro-Oncology > Volume 19, Year 2017 > Number 8, 31 August

Galldiks N, Stegmayr C, Willuweit A, Langen KJ.
Positron emission tomography imaging in diffuse intrinsic pontine glioma.
Ann Transl Med. 2017 Aug;5(15):312→. doi: 10.21037/atm.2017.05.02→. PMID: 28856152→. Editorial. ˍ
Refers to: Kossatz S, et al., Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models.
Cancer Res. 2017 Jan 20, 2017;77(8):2112-2123→. doi: 10.1158/0008-5472.CAN-16-2850→. PMID: 28108511→. Laboratory investigation. ˍ

Sidaway P.
CNS cancer: Glioblastoma subtypes revisited.
Nat Rev Clin Oncol. 2017 Aug 1, 2017;14(10):587→. doi: 10.1038/nrclinonc.2017.122→. PMID: 28762385→. Comment. ˍ
Refers to: Wang Q et al., Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
Cancer Cell. 2017 Jul 10, 2017;32(1):42-56.e6→. doi: 10.1016/j.ccell.2017.06.003→. PMID: 28697342→. Laboratory investigation. ˍ

Veneroni L, Boschetti L, Barretta F, Clerici CA, Simonetti F, Schiavello E, Biassoni V, Spreafico F, Gandola L, Pecori E, Diletto B, Poggi G, Gariboldi F, Sensi R, Massimino M.
Quality of life in long-term survivors treated for metastatic medulloblastoma with a hyperfractionated accelerated radiotherapy (HART) strategy.
Childs Nerv Syst. 2017 Aug 2, 2017;33(11):1969-1976→. doi: 10.1007/s00381-017-3548-1→. PMID: 28770391→. Observational study. ˍ

Iorio AL, da Ros M, Genitori L, Lucchesi M, Colelli F, Signorino G, Cardile F, Laffi G, de Martino M, Pisano C, Sardi I.
Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma.
Oncotarget. 2017 Aug 3, 2017;8(52):89595-89606→. doi: 10.18632/oncotarget.19875→. PMID: 29163773→. Laboratory investigation. ˍ

Schiff D.
Benefit with adjuvant chemotherapy in anaplastic astrocytoma.
Lancet. 2017 Aug 8, 2017;390(10103):1625-1626→. doi: 10.1016/S0140-6736(17)31477-0→. PMID: 28801187→. Comment. ˍ
Refers to: van den Bent MJ et al, Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Lancet. 2017 Aug 8, 2017;390(10103):1645-1653→. doi: 10.1016/S0140-6736(17)31442-3→. PMID: 28801186→. Interventional study. ˍ

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Lancet. 2017 Aug 8, 2017;390(10103):1645-1653→. doi: 10.1016/S0140-6736(17)31442-3→. PMID: 28801186→. Interventional study. ˍ

Zhou Z, Howard TA, Villano JL.
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
Cancer Chemother Pharmacol. 2017 Aug 8, 2017;80(5):1043-1046→. doi: 10.1007/s00280-017-3415-5→. PMID: 28791452→. Case report. ˍ

D'Amico RS, Praver M, Zanazzi GJ, Englander Z, Sims JS, Samanamud JL, Ogden AT, McCormick PC, Feldstein NA, McKhann GM 2nd, Sisti MB, Canoll P, Bruce JN.
Subependymomas are low-grade heterogeneous glial neoplasms defined by subventricular zone lineage markers.
World Neurosurg. 2017 Aug 10, 2017;107:451-463→. doi: 10.1016/j.wneu.2017.08.009→. PMID: 28804038→. Observational study. ˍ

Keil VC, Warmuth-Metz M, Reh C, Enkirch SJ, Reinert C, Beier D, Jones DTW, Pietsch T, Schild HH, Hattingen E, Hau P.
Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype.
AJNR Am J Neuroradiol. 2017 Aug 10, 2017;38(10):1892-1898→. doi: 10.3174/ajnr.A5313→. PMID: 28798218→. Interventional study. ˍ

Hsieh SY, Chan DT, Kam MK, Loong HH, Tsang WK, Poon DM, Ng SC, Poon WS.
Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Hong Kong Med J. 2017 Aug 11, 2017;23(6):594-8→. doi: 10.12809/hkmj165002→. PMID: 28798282→. Observational study. ˍ

An J, Yan H, Li X, Tan R, Chen X, Zhang Z, Liu Y, Zhang P, Lu H, Liu Y.
The inhibiting effect of neural stem cells on proliferation and invasion of glioma cells.
Oncotarget. 2017 Aug 14, 2017;8(44):76949-76960→. doi: 10.18632/oncotarget.20270→. PMID: 29100360→. Laboratory investigation. ˍ

Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T, Scully T, Mahadevan D, Ahmadi MM.
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Cancer Chemother Pharmacol. 2017 Aug 14, 2017;80(4):715-721→. doi: 10.1007/s00280-017-3405-7→. PMID: 28808777→. Interventional study. ˍ

Ishihara M, Yamamoto K, Miwa H, Nishi M.
Spontaneous complete regression of a brain stem glioma pathologically diagnosed as a high-grade glioma.
Childs Nerv Syst. 2017 Aug 14, 2017;33(12):2177-2180→. doi: 10.1007/s00381-017-3570-3→. PMID: 28808781→. Case report. ˍ

Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF.
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
Neuro Oncol. 2017 Aug 14, 2018;20(2):249-258→. doi: 10.1093/neuonc/nox154→. PMID: 29016998→. Interventional study. ˍ

Hassanzadeh C, Rao YJ, Chundury A, Rowe J, Ponisio MR, Sharma A, Miller-Thomas M, Tsien CI, Ippolito JE.
Multiparametric MRI and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Imaging Is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma.
Front Oncol. 2017 Aug 18, 2017;7:178→. doi: 10.3389/fonc.2017.00178→. PMID: 28868256→. Observational study. ˍ

Kaloshi G, Petrela M.
Letter to the Editor. An extent of resection threshold for recurrent glioblastoma: why wait until recurrence?
J Neurosurg. 2017 Aug 18, 2017;127(5):1200→. doi: 10.3171/2017.6.JNS14868→. PMID: 28820302→. Letter to the Editor. ˍ
Refers to: Oppenlander ME, et al., An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.
J Neurosurg. 2014 Jan 31, 2014;120(4):846-53→. doi: 10.3171/2013.12.JNS13184→. PMID: 24484232→. Observational study; ˍ

Stritzelberger J, Distel L, Buslei R, Fietkau R, Putz F.
Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Clin Transl Oncol. 2017 Aug 20, 2018;20(4):508-516→. doi: 10.1007/s12094-017-1743-x→. PMID: 28825189→. Laboratory investigation. ˍ

Dagmar D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P.
Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
Neuro Oncol. 2017 Aug 21, 2018;20(3):400-410→. doi: 10.1093/neuonc/nox155→. PMID: 29016837→. Interventional study. ˍ

Mora J, Perez-Jaume S, Cruz O.
Treatment of childhood astrocytomas with irinotecan and cisplatin.
Clin Transl Oncol. 2017 Aug 21, 2018;20(4):500-507→. doi: 10.1007/s12094-017-1741-z→. PMID: 28828715→. Observational study. ˍ

Khagi S, Miller CR.
Putting "multiforme" back into glioblastoma: intratumoral transcriptome heterogeneity is a consequence of its complex morphology.
Neuro Oncol. 2017 Aug 23, 2017;19(12):1570-1571→. doi: 10.1093/neuonc/nox131→. PMID: 2901683→. Comment. ˍ
Refers to: Prabhu A, et al., Histologically defined intratumoral sequencing uncovers evolutionary cues into conserved molecular events driving gliomagenesis.
Neuro Oncol. 2017 May 25, 2017;19(12):1599-1606→. doi: 10.1093/neuonc/nox100→. PMID: 28541485→. Laboratory investigation. ˍ

Patay Z, Merchant TE, Nguyen R, Pierson CR, Onar-Thomas A, Broniscer A.
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.
Int J Radiat Oncol Biol Phys. 2017 Aug 24, 2017;99(5):1295-1305→. doi: 10.1016/j.ijrobp.2017.08.021→. PMID: 29165288→. Observational study. ˍ

Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A; Zvi Ram on behalf of the EF-14 Trial Investigators.
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
J Neurooncol. 2017 Aug 28, 2017;135(3):545-552→. doi: 10.1007/s11060-017-2601-y→. PMID: 28849310→. Interventional study. ˍ

*

Alotaibi NM, Samuel N, Mansouri A, Nejad R, Macdonald RL.
Glioblastoma Following Ischemic Stroke.
Can J Neurol Sci. 2017 Aug 30, 2017;44(6):732-733→. doi: 10.1017/cjn.2017.220→. PMID: 29391081→. Case report. ˍ

*

Lan X, Jörg DJ, Cavalli FMG, Richards LM, Nguyen LV, Vanner RJ, Guilhamon P, Lee L, Kushida MM, Pellacani D, Park NI, Coutinho FJ, Whetstone H, Selvadurai HJ, Che C, Luu B, Carles A, Moksa M, Rastegar N, Head R, Dolma S, Prinos P, Cusimano MD, Das S, Bernstein M, Arrowsmith CH, Mungall AJ, Moore RA, Ma Y, Gallo M, Lupien M, Pugh TJ, Taylor MD, Hirst M, Eaves CJ, Simons BD, Dirks PB.
Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy.
Nature. 2017 Aug 30, 2017;549(7671):227-232→. doi: 10.1038/nature23666→. PMID: 28854171→. Laboratory investigation. ˍ